Regeneron Pharmaceuticals gets good marketing news


Regeneron Pharmaceuticals said that European officials recommended granting marketing authorization for its colorectal cancer treatment, Zaltrap. The injectable drug would be used to treat adults. The US Food and Drug Administration approved Zaltrap in August, and marketing authorization applications are under review with other agencies around the world, Regeneron said.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of